Literature DB >> 20098301

Terminating prolonged refractory status epilepticus using ketamine.

Cheng-Yang Hsieh1, Pi-Shan Sung, Jing-Jane Tsai, Chin-Wei Huang.   

Abstract

Refractory status epilepticus (RSE) is an emergent and difficult neurologic problem that is not uncommon in clinical practice. In this report, we describe a 23-year-old man whose RSE was refractory to standard antiepileptic drugs and barbiturates; it was successfully terminated only with intravenous ketamine. In this report, we evaluated and discuss the clinical and electroencephalographic effects under ketamine. This case and the rare cases of ketamine experience in RSE reported in the literature show that ketamine is potentially effective to use when treating patients with RSE. Further clinical trials are warranted, however.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20098301     DOI: 10.1097/WNF.0b013e3181d1e3cd

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  12 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

2.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

3.  Endothelial Von Willebrand factor promotes blood-brain barrier flexibility and provides protection from hypoxia and seizures in mice.

Authors:  Georgette L Suidan; Alexander Brill; Simon F De Meyer; Jaymie R Voorhees; Stephen M Cifuni; Jessica E Cabral; Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07-03       Impact factor: 8.311

4.  Early ketamine to treat refractory status epilepticus.

Authors:  Andreas H Kramer
Journal:  Neurocrit Care       Date:  2012-04       Impact factor: 3.210

5.  Ketamine to treat super-refractory status epilepticus.

Authors:  Ayham Alkhachroum; Caroline A Der-Nigoghossian; Elizabeth Mathews; Nina Massad; Riva Letchinger; Kevin Doyle; Wei-Ting Chiu; Julie Kromm; Clio Rubinos; Angela Velazquez; David Roh; Sachin Agarwal; Soojin Park; E Sander Connolly; Jan Claassen
Journal:  Neurology       Date:  2020-09-01       Impact factor: 9.910

Review 6.  NMDA antagonists for refractory seizures.

Authors:  F A Zeiler; J Teitelbaum; L M Gillman; M West
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

7.  Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study.

Authors:  Nicolas Gaspard; Brandon Foreman; Lilith M Judd; James N Brenton; Barnett R Nathan; Blathnaid M McCoy; Ali Al-Otaibi; Ronan Kilbride; Ivan Sánchez Fernández; Lucy Mendoza; Sophie Samuel; Asma Zakaria; Giridhar P Kalamangalam; Benjamin Legros; Jerzy P Szaflarski; Tobias Loddenkemper; Cecil D Hahn; Howard P Goodkin; Jan Claassen; Lawrence J Hirsch; Suzette M Laroche
Journal:  Epilepsia       Date:  2013-06-12       Impact factor: 5.864

8.  Practice variations in the management of status epilepticus.

Authors:  Aaron M Cook; Amber Castle; Amy Green; Christine Lesch; Christopher Morrison; Denise Rhoney; Dennis Parker; Eljim Tesoro; Gretchen Brophy; Haley Goodwin; Jane Gokun; Jason Makii; Karen McAllen; Kathleen Bledsoe; Kiranpal Sangha; Kyle Weant; Norah Liang; Teresa Murphy-Human
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

Review 9.  Pharmacotherapy for Status Epilepticus.

Authors:  Eugen Trinka; Julia Höfler; Markus Leitinger; Francesco Brigo
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

10.  Choice of anesthesia in molybdenum cofactor deficiency: A case report.

Authors:  Metin Alkan; Gülay Kip; Şaziye Şahin; Didem Atabek
Journal:  J Res Med Sci       Date:  2014-11       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.